A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

StatusRecruiting

PhasePhase 3

SponsorMerck Sharp & Dohme LLC

Started2024-10-21

View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 68 record versions are listed below. See every version on ClinicalTrials.gov ↗

2026-08-25

Study Status, Contacts/Locations v67

Study sitesdetails revised at 1 of 241 sites

2026-08-20

Study Status v66

Re-verified, no change to tracked fields

2026-08-06

Study Status, Contacts/Locations v65

Study sites239→241

2026-07-30

Study Status, Contacts/Locations v64

Study sites238→239

2026-07-24

Study Status, Contacts/Locations v63

Study sites236→238

Show 45 earlier versions

2026-07-01

Study Status, Contacts/Locations v62

Study sites235→236

2026-06-24

Study Status, Contacts/Locations v61

Study sites233→235

2026-06-17

Study Status, Contacts/Locations v60

Study sites232→233

2026-05-13

Study Status, Contacts/Locations v59

Study sites231→232

2026-05-01

Study Status, Contacts/Locations v58

Study sitesdetails revised at 1 of 231 sites

2026-04-22

Study Status, Contacts/Locations v57

Study sites229→231

2026-04-17

Study Status, Contacts/Locations v56

Study sitesdetails revised at 2 of 229 sites

2026-04-10

Study Status, Contacts/Locations v55

Study sites228→229

2026-04-03

Study Status, Contacts/Locations v54

Study sites227→228

2026-03-27

Study Status, Contacts/Locations v53

Study sitesdetails revised at 1 of 227 sites

2026-03-20

Study Status, Contacts/Locations v52

Study sites225→227

2026-03-10

Study Status, Eligibility, Contacts/Locations v51

Study sites222→225

Eligibility criteria+34 characters

[...] previously untreated and pathologically confirmed resectable clinical Stage II, IIIA, or IIIB (N2) non-small cell lung cancer (NS [...] include but are not limited to the following: Diagnosis of small cell lung cancer (SCLC) or, for mixed tumors, presence of small cell elements, or h [...]

2026-02-20

Study Status, Contacts/Locations v50

Study sites221→222

2026-02-13

Study Status, Contacts/Locations v49

Study sites219→221

2026-02-06

Study Status, Contacts/Locations v48

Study sites218→219

2026-01-30

Study Status, Contacts/Locations v47

Study sites213→218

2026-01-23

Study Status, Contacts/Locations v46

Study sites209→213

2026-01-16

Study Status, Contacts/Locations v45

Study sites208→209

2026-01-02

Study Status, Contacts/Locations v44

Study sitescontacts updated at 3 of 208 sites

2025-12-23

Study Status, Contacts/Locations v43

Study sites206→208

2025-12-17

Study Status, Contacts/Locations v42

Study sites205→206

2025-12-09

Study Status, Contacts/Locations v41

Study sites203→205

2025-12-03

Study Status, Contacts/Locations v40

Study sites200→203

2025-11-20

Study Status, Contacts/Locations v39

Study sites198→200

2025-11-12

Study Status, Contacts/Locations v38

Study sites195→198

2025-11-07

Study Status, Contacts/Locations v37

Study sites192→195

2025-10-29

Study Status, Contacts/Locations v36

Study sites188→192

2025-10-24

Study Status, Contacts/Locations v35

Study sites184→188

2025-10-15

Study Status, Contacts/Locations v34

Study sites180→184

2025-10-03

Study Status, Contacts/Locations v33

Study sites176→180

2025-09-22

Study Status, Contacts/Locations v32

Study sites171→176

2025-09-09

Study Status, Contacts/Locations v31

Study sites166→171

2025-08-27

Study Status, Contacts/Locations v30

Study sites156→166

2025-08-13

Study Status, Contacts/Locations v29

Study sites152→156

2025-07-30

Study Status, Contacts/Locations v28

Study sites149→152

2025-07-24

Study Status, Contacts/Locations v27

Study sites144→149

2025-07-16

Study Status, Contacts/Locations v26

Study sites141→144

2025-07-10

Study Status, Contacts/Locations v25

Study sites134→141

2025-07-03

Study Status, Contacts/Locations v24

Study sites129→134

2025-06-19

Study Status, Contacts/Locations v23

Study sites124→129

2025-06-12

Study Identification, Study Status, Contacts/Locations v22

Study sites109→124

2025-06-06

Study Status, Contacts/Locations v21

Study sites103→109

2025-05-30

Study Status, Contacts/Locations v20

Study sites93→103

2025-05-23

Study Status, Contacts/Locations v19

Study sites79→93

2025-05-14

Study Status, Contacts/Locations v18

Study sites78→79

Merck (MSD)

401 trials monitored

See 24 trials at risk

Lung Cancer

4,033 trials monitored

See 210 trials at risk

Non-Small Cell Lung Cancer (NSCLC)

2,914 trials monitored

See 156 trials at risk

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).

Trial Details

NCT Number	NCT06623422
Lead Sponsor	Merck Sharp & Dohme LLC Collaborators: ModernaTX, Inc.
Conditions	Carcinoma, Non-Small-Cell Lung
Enrollment	680 participants
Start Date	2024-10-21
Primary Completion	2033-05-16 (estimated)
Study Completion	2038-01-26 (estimated)
Updated on ClinicalTrials.gov	2026-09-28